Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen
- PMID: 10543973
- DOI: 10.1006/jmbi.1999.3192
Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen
Abstract
The Fab portion of a humanized antibody (Fab-12; IgG form known as rhuMAb VEGF) to vascular endothelial growth factor (VEGF) has been affinity-matured through complementarity-determining region (CDR) mutation, followed by affinity selection using monovalent phage display. After stringent binding selections at 37 degrees C, with dissociation (off-rate) selection periods of several days, high affinity variants were isolated from CDR-H1, H2, and H3 libraries. Mutations were combined to obtain cumulatively tighter-binding variants. The final variant identified here, Y0317, contained six mutations from the parental antibody. In vitro cell-based assays show that four mutations yielded an improvement of about 100-fold in potency for inhibition of VEGF-dependent cell proliferation by this variant, consistent with the equilibrium binding constant determined from kinetics experiments at 37 degrees C. Using X-ray crystallography, we determined a high-resolution structure of the complex between VEGF and the affinity-matured Fab fragment. The overall features of the binding interface seen previously with wild-type are preserved, and many contact residues are maintained in precise alignment in the superimposed structures. However, locally, we see evidence for improved contacts between antibody and antigen, and two mutations result in increased van der Waals contact and improved hydrogen bonding. Site-directed mutants confirm that the most favorable improvements as judged by examination of the complex structure, in fact, have the greatest impact on free energy of binding. In general, the final antibody has improved affinity for several VEGF variants as compared with the parental antibody; however, some contact residues on VEGF differ in their contribution to the energetics of Fab binding. The results show that small changes even in a large protein-protein binding interface can have significant effects on the energetics of interaction.
Copyright 1999 Academic Press.
Similar articles
-
Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor.J Mol Biol. 2002 Feb 22;316(3):769-87. doi: 10.1006/jmbi.2001.5370. J Mol Biol. 2002. PMID: 11866530
-
Dissection of binding interactions in the complex between the anti-lysozyme antibody HyHEL-63 and its antigen.Biochemistry. 2003 Jan 14;42(1):11-22. doi: 10.1021/bi020589+. Biochemistry. 2003. PMID: 12515535
-
VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.Structure. 1998 Sep 15;6(9):1153-67. doi: 10.1016/s0969-2126(98)00116-6. Structure. 1998. PMID: 9753694
-
Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-gamma-interferon antibody.J Mol Recognit. 1999 Jan-Feb;12(1):19-32. doi: 10.1002/(SICI)1099-1352(199901/02)12:1<19::AID-JMR445>3.0.CO;2-Y. J Mol Recognit. 1999. PMID: 10398393 Review.
-
The structural basis of antigen-antibody recognition.Annu Rev Biophys Biophys Chem. 1987;16:139-59. doi: 10.1146/annurev.bb.16.060187.001035. Annu Rev Biophys Biophys Chem. 1987. PMID: 2439094 Review.
Cited by
-
A brief history of anti-VEGF for the treatment of ocular angiogenesis.Am J Pathol. 2012 Aug;181(2):376-9. doi: 10.1016/j.ajpath.2012.06.006. Epub 2012 Jun 29. Am J Pathol. 2012. PMID: 22749677 Free PMC article. Review.
-
A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients.Cancer Chemother Pharmacol. 2015 Apr;75(4):791-803. doi: 10.1007/s00280-015-2701-3. Epub 2015 Feb 17. Cancer Chemother Pharmacol. 2015. PMID: 25687989 Free PMC article.
-
The effect of bevacizumab versus ranibizumab in the treatment of corneal neovascularization: a preliminary study.Korean J Ophthalmol. 2013 Aug;27(4):235-42. doi: 10.3341/kjo.2013.27.4.235. Epub 2013 Jul 5. Korean J Ophthalmol. 2013. PMID: 23908568 Free PMC article. Clinical Trial.
-
Multiplex epitope mapping using bacterial surface display reveals both linear and conformational epitopes.Sci Rep. 2012;2:706. doi: 10.1038/srep00706. Epub 2012 Oct 4. Sci Rep. 2012. PMID: 23050090 Free PMC article.
-
Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK.Clin Ophthalmol. 2008 Jun;2(2):347-54. doi: 10.2147/opth.s2601. Clin Ophthalmol. 2008. PMID: 19668726 Free PMC article.
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources